Stefan Michiels
#162,384
Most Influential Person Now
Researcher
Stefan Michiels's AcademicInfluence.com Rankings
Stefan Michielsmathematics Degrees
Mathematics
#7393
World Rank
#10062
Historical Rank
Statistics
#847
World Rank
#938
Historical Rank
Measure Theory
#2123
World Rank
#2566
Historical Rank
Download Badge
Mathematics
Stefan Michiels's Degrees
- PhD Biostatistics University of Amsterdam
- Masters Mathematics University of Amsterdam
- Bachelors Mathematics University of Amsterdam
Similar Degrees You Can Earn
Why Is Stefan Michiels Influential?
(Suggest an Edit or Addition)Stefan Michiels's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. (2013) (1281)
- Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. (2014) (1032)
- Prediction of cancer outcome with microarrays: a multiple random validation strategy (2005) (1026)
- Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. (2010) (733)
- CD4⁺ follicular helper T cell infiltration predicts breast cancer survival. (2013) (712)
- Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. (2014) (684)
- Gene expression profiling of primary cutaneous melanoma and clinical outcome. (2006) (481)
- False discovery rate, sensitivity and sample size for microarray studies (2005) (478)
- High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. (2017) (465)
- Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial. (2015) (456)
- Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO Precision Medicine Working Group. (2020) (432)
- Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothe (2017) (408)
- Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. (2004) (380)
- Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. (2019) (345)
- Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. (2004) (339)
- Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array (2009) (326)
- Progression-free survival is a surrogate for survival in advanced colorectal cancer. (2007) (324)
- Elucidating Prognosis and Biology of Breast Cancer Arising in Young Women Using Gene Expression Profiling (2012) (308)
- Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. (2017) (270)
- Precision medicine for metastatic breast cancer—limitations and solutions (2015) (262)
- Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. (2012) (252)
- A meta-analysis of individual patient data from randomized trials assessing chemotherapy with and without estramustine in patients with castration-refractory prostate cancer. (2006) (228)
- Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. (2014) (221)
- Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. (2017) (215)
- Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. (2012) (205)
- DNA methylation profiling reveals a predominant immune component in breast cancers (2011) (202)
- HER2-Positive Circulating Tumor Cells in Breast Cancer (2011) (196)
- Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group (2016) (189)
- Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer (2019) (188)
- Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. (2009) (185)
- Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data (2013) (182)
- Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis (2018) (173)
- The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. (2019) (172)
- Multifactorial approach to predicting resistance to anthracyclines. (2011) (170)
- Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer. (2018) (168)
- Predictors of responses to immune checkpoint blockade in advanced melanoma (2017) (162)
- Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data. (2009) (145)
- Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis. (2013) (142)
- Meta-analysis when only the median survival times are known: A comparison with individual patient data results (2005) (138)
- Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†. (2015) (135)
- Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast Cancer (2013) (133)
- Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. (2013) (130)
- Integrating biomarkers in clinical trials (2011) (125)
- Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement. (2013) (124)
- The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer. (2014) (118)
- Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. (2007) (115)
- Gene expression profiling: does it add predictive accuracy to clinical characteristics in cancer prognosis? (2007) (109)
- The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice (2020) (108)
- Biomarker studies: a call for a comprehensive biomarker study registry (2011) (107)
- Interpretation of microarray data in cancer (2007) (106)
- Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning. (2018) (105)
- Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial. (2017) (103)
- The European Society for Medical Oncology (ESMO) Precision Medicine Glossary. (2018) (99)
- Uncertain benefit from surgery in patients with lung metastases from breast carcinoma (2004) (93)
- CD 4 + follicular helper T cell infiltration predicts breast cancer survival (2013) (91)
- Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials. (2007) (88)
- Follicular thyroid tumors with the PAX8-PPARgamma1 rearrangement display characteristic genetic alterations. (2005) (86)
- Bias in the estimation of false discovery rate in microarray studies (2005) (86)
- Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer (2019) (84)
- Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 'triple-negative' breast cancers. (2007) (83)
- PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer (2013) (82)
- Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy. (2019) (82)
- Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy. (2019) (82)
- Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE). (2017) (78)
- Polymorphism discovery in 62 DNA repair genes and haplotype associations with risks for lung and head and neck cancers. (2007) (76)
- Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial (2017) (75)
- Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis. (2013) (73)
- Sodium/iodide symporter (NIS) gene expression is the limiting step for the onset of thyroid function in the human fetus. (2007) (72)
- Immunohistochemichal expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer. (2007) (72)
- Local recurrence after curative resection in patients with colon and rectal cancers (2008) (70)
- A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints. (2012) (69)
- Differential expression of biomarkers in lung adenocarcinoma: a comparative study between smokers and never-smokers. (2005) (69)
- The impact of anti-inflammatory agents on the outcome of patients with colorectal cancer. (2014) (68)
- A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups (2017) (68)
- Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial. (2016) (66)
- CXCR4 expression in early breast cancer and risk of distant recurrence. (2009) (66)
- Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data. (2018) (66)
- Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology (2014) (66)
- Empirical extensions of the lasso penalty to reduce the false discovery rate in high‐dimensional Cox regression models (2016) (64)
- Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis. (2019) (64)
- Individual patient data-based meta-analysis assessing pre-operative chemotherapy in resectable oesophageal carcinoma (2007) (63)
- Robotic Prophylactic Nipple-Sparing Mastectomy with Immediate Prosthetic Breast Reconstruction: A Prospective Study (2018) (63)
- The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer. (2014) (61)
- Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis. (2009) (61)
- Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer (2020) (60)
- Individual- and trial-level surrogacy in colorectal cancer (2008) (58)
- Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk (2020) (54)
- Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group (2020) (54)
- The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group (2021) (54)
- Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy (2019) (54)
- Investigating trial and treatment heterogeneity in an individual patient data meta‐analysis of survival data by means of the penalized maximum likelihood approach (2008) (53)
- EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer. (2019) (52)
- Loss of microRNA-200a and c, and microRNA-203 expression at the invasive front of primary cutaneous melanoma is associated with increased thickness and disease progression (2012) (52)
- The journey of tumor infiltrating lymphocytes (TIL) as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition. (2021) (51)
- Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (2013) (51)
- Characterization and Clinical Evaluation of CD10+ Stroma Cells in the Breast Cancer Microenvironment (2012) (51)
- Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy. (2019) (50)
- Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas (2008) (50)
- International study on inter-reader variability for circulating tumor cells in breast cancer (2014) (49)
- Body mass index and 20 specific cancers: re-analyses of dose–response meta-analyses of observational studies (2017) (48)
- Surrogate End Points for Overall Survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma: An Individual Patient Data Meta-analysis (2017) (46)
- Tutorial in Joint Modeling and Prediction: a Statistical Software for Correlated Longitudinal Outcomes, Recurrent Events and a Terminal Event (2017) (46)
- Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy. (2019) (45)
- Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers. (2016) (45)
- Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy. (2019) (45)
- Abstract S1-05: Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC) (2013) (43)
- A gene signature for late distant metastasis in breast cancer identifies a potential mechanism of late recurrences (2013) (43)
- Prediction of cancer outcome with microarrays (2005) (43)
- Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis. (2019) (42)
- Tumour invasiveness, the local and systemic environment and the basis of staging systems in colorectal cancer (2017) (42)
- Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. (2012) (41)
- Genetic polymorphisms in 85 DNA repair genes and bladder cancer risk. (2009) (40)
- Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non-small cell lung cancer. (2020) (40)
- A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer (2018) (40)
- Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trial (2018) (39)
- Double primary malignancy in colorectal cancer patients—MSI is the useful marker for predicting double primary tumors (2009) (39)
- Random effects survival models gave a better understanding of heterogeneity in individual patient data meta-analyses. (2005) (39)
- Genomic grade adds prognostic value in invasive lobular carcinoma. (2013) (39)
- Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease. (2007) (38)
- A joint model for the dependence between clustered times to tumour progression and deaths: A meta-analysis of chemotherapy in head and neck cancer (2015) (37)
- Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis (2016) (37)
- Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells (2020) (36)
- Self-Supervised Nuclei Segmentation in Histopathological Images Using Attention (2020) (35)
- Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission (2011) (35)
- Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials). (2015) (35)
- Abstract S1-03: Pooled individual patient data analysis of stromal tumor infiltrating lymphocytes in primary triple negative breast cancer treated with anthracycline-based chemotherapy (2016) (34)
- Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer. (2008) (34)
- Joint model for left‐censored longitudinal data, recurrent events and terminal event: Predictive abilities of tumor burden for cancer evolution with application to the FFCD 2000–05 trial (2016) (33)
- Statistical controversies in clinical research: prognostic gene signatures are not (yet) useful in clinical practice (2016) (33)
- Steps forward for cancer precision medicine (2017) (33)
- Biomarker Discovery and Validation: Statistical Considerations. (2021) (32)
- Tumor-In fi ltrating Lymphocytes and Prognosis : A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers (2019) (31)
- Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort. (2018) (31)
- Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer. (2016) (31)
- Expression and possible role of hPTTG1/securin in cutaneous malignant melanoma (2006) (30)
- Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors (2017) (29)
- Association between SPARC mRNA Expression, Prognosis and Response to Neoadjuvant Chemotherapy in Early Breast Cancer: A Pooled in-silico Analysis (2013) (29)
- Multidimensionality of microarrays: Statistical challenges and (im)possible solutions (2011) (28)
- Cost effectiveness of molecular profiling for adjuvant decision making in patients with node-negative breast cancer. (2014) (28)
- surrosurv: An R package for the evaluation of failure time surrogate endpoints in individual patient data meta-analyses of randomized clinical trials (2018) (28)
- A novel tumor‐based epithelial‐to‐mesenchymal transition score that associates with prognosis and metastasis in patients with Stage II/III colorectal cancer (2018) (27)
- Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer (2020) (27)
- Comparison of the prognostic value of measures of the tumor inflammatory cell infiltrate and tumor-associated stroma in patients with primary operable colorectal cancer (2016) (26)
- A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer (2013) (26)
- Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group (2020) (26)
- Reporting of time-to-event end points and tracking of failures in randomized trials of radiotherapy with or without any concomitant anticancer agent for locally advanced head and neck cancer. (2009) (25)
- ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors (2018) (25)
- Societal challenges of precision medicine: Bringing order to chaos. (2017) (25)
- The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence. (2016) (25)
- Variants in DNA double‐strand break repair and DNA damage‐response genes and susceptibility to lung and head and neck cancers (2008) (25)
- Identification of biomarker‐by‐treatment interactions in randomized clinical trials with survival outcomes and high‐dimensional spaces (2016) (25)
- Improved Treatment of Breast Cancer with Anti-HER2 Therapy Requires Interleukin-21 Signaling in CD8+ T Cells. (2016) (24)
- Tumor PIK3CA mutations, lymphocyte infiltration, and recurrence-free survival (RFS) in early breast cancer (BC): Results from the FinHER trial. (2012) (23)
- Application of an acceptance sampling plan for post-production quality control of chemotherapeutic batches in an hospital pharmacy. (2006) (22)
- Surrogate End Points for Overall Survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma: An Individual Patient Data Meta-analysis. (2017) (21)
- Expression of erythropoietin and its receptor in neuroblastomas (2007) (21)
- The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene (2016) (21)
- Activation of the phosphatidylinositol 3'-kinase/AKT pathway in neuroblastoma and its regulation by thioredoxin 1. (2011) (21)
- WITHDRAWN: Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease. (2012) (21)
- Postoperative adjuvant therapy for stage II non-small-cell lung cancer. (1999) (20)
- HEX, PAX‐8 and TTF‐1 gene expression in human thyroid tissues: a comparative analysis with other genes involved in iodide metabolism (2006) (18)
- A benchmark study of scoring methods for non‐coding mutations (2018) (18)
- Impact of COVID-19 on healthcare organisation and cancer outcomes (2021) (18)
- The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies (2022) (18)
- Mutation-Independent Activation of the Anaplastic Lymphoma Kinase in Neuroblastoma. (2016) (18)
- Abstract OT2-6-08: Phase II, randomized, parallel-cohort study of neoadjuvant buparlisib (BKM120) in combination with trastuzumab and paclitaxel in women with HER2-positive, PIK3CA mutant and PIK3CA wild-type primary breast cancer – NeoPHOEBE (2013) (18)
- Fatigue and physical activity in cancer survivors: A cross‐sectional population‐based study (2019) (18)
- Omics-based clinical trial designs (2013) (17)
- Genomic Grade Index (GGI): Feasibility in Routine Practice and Impact on Treatment Decisions in Early Breast Cancer (2013) (17)
- Multivariate Modelling Reveals Evidence of a Dose-Response Relationship in Phase 2 Studies of Single-Agent Carfilzomib (2011) (17)
- A Dual Model for Prioritizing Cancer Mutations in the Non-coding Genome Based on Germline and Somatic Events (2015) (17)
- Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer (2022) (17)
- Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door. (2018) (16)
- Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer (2016) (16)
- Image-guided tumour biopsies in a prospective molecular triage study (MOSCATO-01): What are the real risks? (2018) (16)
- Added Value of Whole-Exome and Transcriptome Sequencing for Clinical Molecular Screenings of Advanced Cancer Patients With Solid Tumors. (2018) (16)
- Multiple testing of treatment‐effect‐modifying biomarkers in a randomized clinical trial with a survival endpoint (2011) (15)
- Statistical controversies in clinical research: overlap and errors in the meta-analyses of microRNA genetic association studies in cancers (2017) (15)
- Towards understanding the breast cancer epigenome: a comparison of genome-wide DNA methylation and gene expression data (2015) (14)
- Reactive stroma and trastuzumab resistance in HER2‐positive early breast cancer (2020) (13)
- 159O Prognostic value of tumour infiltrating lymphocytes in young triple negative breast cancer patients who did not receive adjuvant systemic treatment; by the PARADIGM study group (2020) (13)
- Establishing the Evidence Bar for Molecular Diagnostics in Personalised Cancer Care (2015) (13)
- Mining the coding and non-coding genome for cancer drivers. (2015) (13)
- Genomic grade adds prognostic value in invasive lobular carcinoma. (2013) (12)
- Short-term outcomes of a multicentre randomized clinical trial comparing laparoscopic pylorus-preserving gastrectomy with laparoscopic distal gastrectomy for gastric cancer (the KLASS-04 trial). (2021) (12)
- A Poisson approach to the validation of failure time surrogate endpoints in individual patient data meta-analyses (2019) (12)
- Abstract CT041: Anti-proliferative response and predictive biomarkers to palbociclib in early breast cancer: The Preoperative Palbociclib (POP) randomized trial (2016) (12)
- New insights into the evaluation of randomized controlled trials for rare diseases over a long‐term research horizon: a simulation study (2016) (12)
- Changes in weight, physical and psychosocial patient-reported outcomes among obese women receiving treatment for early-stage breast cancer: A nationwide clinical study (2020) (12)
- Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy (2022) (11)
- Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report (2020) (11)
- Abstract S3-01: IMENEO: International MEta-analysis of circulating tumor cell detection in early breast cancer patients treated by NEOadjuvant chemotherapy (2017) (11)
- Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers (2018) (10)
- biospear: an R package for biomarker selection in penalized Cox regression (2018) (10)
- Tumor PIK 3 CA Genotype and Prognosis in Early-Stage Breast Cancer : A Pooled Analysis of Individual Patient Data (2018) (10)
- Predictive classifier for intensive treatment of head and neck cancer (2020) (10)
- PIK 3 CA Genotype and a PIK 3 CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer (2012) (10)
- Progression-free survival (PFS) as a surrogate for overall survival (OS) in patients with advanced colorectal cancer: An analysis of 3159 patients randomized in 11 trials (2005) (10)
- Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials (2020) (10)
- Low residual proliferation after short-term letrozole therapy is an early predictive marker of response in high proliferative ER-positive breast cancer. (2011) (10)
- Association between the nuclear to cytoplasmic ratio of p27 and the efficacy of adjuvant polychemotherapy in early breast cancer. (2012) (10)
- A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer (2017) (10)
- A comparison between different prediction models for invasive breast cancer occurrence in the French E3N cohort (2015) (9)
- Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancer. (2018) (9)
- Exploring disparities in incidence and mortality rates of breast and gynecologic cancers according to the Human Development Index in the Pan-American region. (2017) (9)
- Development and Validation of a Predictive Model of Severe Fatigue After Breast Cancer Diagnosis: Toward a Personalized Framework in Survivorship Care (2022) (9)
- Integrating expert's knowledge constraint of time dependent exposures in structure learning for Bayesian networks (2020) (8)
- Comment on ‘Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis' (2014) (8)
- The relationship between aortic calcification and anastomotic leak following gastrointestinal resection: A systematic review. (2019) (8)
- 3133 Prognostic value of texture analysis and correlation with molecular profile in EGFR mutated/ALK rearranged advanced non-small cell lung cancer (NSCLC) (2015) (8)
- Evaluation of Treatment Effect with Paired Failure Times in a Single-Arm Phase II Trial in Oncology (2018) (8)
- Accounting for grouped predictor variables or pathways in high-dimensional penalized Cox regression models (2020) (8)
- Body weight and return to work among survivors of early-stage breast cancer (2020) (8)
- Long-Term Longitudinal Patterns of Patient-Reported Fatigue After Breast Cancer: A Group-Based Trajectory Analysis (2022) (8)
- Quality‐of‐life assessment in French patients with metastatic melanoma in real life (2020) (8)
- Testing the treatment effect on competing causes of death in oncology clinical trials (2014) (8)
- High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer (2021) (7)
- Validation of microarray data by quantitative reverse-transcriptase polymerase chain reaction. (2005) (7)
- Determinants of use of oral complementary-alternative medicine among women with early breast cancer: a focus on cancer-related fatigue (2021) (7)
- Association between FGFR1 copy numbers, MAP3K1 mutations, and survival in axillary node-positive, hormone receptor-positive, and HER2-negative early breast cancer in the PACS04 and METABRIC studies (2019) (7)
- Multivariate joint frailty model for the analysis of nonlinear tumor kinetics and dynamic predictions of death (2018) (7)
- Gene Expression Pro fi ling of Primary Cutaneous Melanoma and Clinical Outcome (2006) (7)
- Oncology clinical trials (2013) (7)
- Abstract CT004: European pediatric precision medicine program in recurrent tumors: first results from MAPPYACTS molecular profiling trial towards AcSe-ESMART proof-of-concept study (2017) (7)
- Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed and/or Refractory Multiple Myeloma. (2015) (6)
- Serum assessment of non-adherence to adjuvant endocrine therapy (ET) among premenopausal patients in the prospective multicenter CANTO cohort. (2018) (6)
- Robust estimation of the expected survival probabilities from high-dimensional Cox models with biomarker-by-treatment interactions in randomized clinical trials (2017) (6)
- Concordance between HER‐2 status determined by qPCR in Fine Needle Aspiration Cytology (FNAC) samples compared with IHC and FISH in Core Needle Biopsy (CNB) or surgical specimens in breast cancer patients (2016) (6)
- Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials (2020) (6)
- Tumor PIK3CA genotype and prognosis: A pooled analysis of 4,241 patients (pts) with early-stage breast cancer (BC) (2015) (6)
- Evaluation of disease-free survival as surrogate endpoint for overall survival using two individual patient data meta-analyses of adjuvant chemotherapy in operable non-small cell lung cancer. (2011) (6)
- Abstract CT101: D-BEYOND: A window of opportunity trial evaluating denosumab, a RANK-ligand (RANKL) inhibitor and its biological effects in young pre-menopausal women diagnosed with early breast cancer (2018) (5)
- Textbook of Clinical Trials in Oncology (2019) (5)
- Development and Validation of Genomic Signatures (2018) (5)
- 217OA gene signature of chemo-immunization to predict outcome in patients with triple negative breast cancer treated with anthracycline-based neoadjuvant chemotherapy (2017) (4)
- Estimating causal effects of time-dependent exposures on a binary endpoint in a high-dimensional setting (2018) (4)
- The impact of circulating tumor cells (CTCs) detection in metastatic breast cancer (MBC): Implications of “indolent” stage IV disease (Stage IVindolent). (2018) (4)
- Uptake of Recommendations for Posttreatment Cancer-Related Fatigue Among Breast Cancer Survivors. (2022) (4)
- Evaluation of the prognostic and predictive value of tumor-infiltrating lymphocytes (TILs) in a phase III randomized adjuvant breast cancer (BC) trial (BIG 2-98) of node-positive (N+) BC comparing the addition of docetaxel to doxorubicin (A-T) with doxorubicin (A)-only chemotherapy (CT). (2011) (4)
- S1-6: Characterization of Breast Cancer Distant Metastasis Based on Outcome over Time Using a Gene Expression Profiling Approach and Identification of Pathway Activities of Late Relapse. (2011) (4)
- Penalized Poisson model for network meta‐analysis of individual patient time‐to‐event data (2021) (4)
- Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancer (2022) (4)
- Expression of erythropoietin and its receptor in neuroblastomas. (2006) (4)
- Taking into account successive treatment lines in the analysis of a colorectal cancer randomised trial. (2013) (4)
- Prognostic value of tumour infiltrating lymphocytes (TILs) in patients with early-stage triple negative breast cancers (TNBC) in the absence of chemotherapy (2019) (4)
- CD44+ CD24-/low phenotype and resistance to trastuzumab in HER2-positive breast cancer cell lines. (2011) (4)
- Can pediatric and adolescent patients with recurrent tumors benefit from a precision medicine program? The European MAPPYACTS experience. (2019) (4)
- Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patients (2013) (4)
- 3127 Prognostic value of texture analysis in advanced non-small cell lung cancer (NSCLC) (2015) (4)
- Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer patients (2021) (4)
- Association between the nuclear to cytoplasmic ratio of p27 and the efficacy of adjuvant polychemotherapy in early breast cancer. (2012) (4)
- Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy (2020) (4)
- A phase III randomized trial of weight loss to reduce cancer-related fatigue among overweight and obese breast cancer patients: MEDEA Study design (2022) (4)
- Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy. (2020) (4)
- Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group (2021) (4)
- Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology (2014) (4)
- Prediction of Breast Cancer Treatment–Induced Fatigue by Machine Learning Using Genome-Wide Association Data (2020) (3)
- Abstract CT081: Pediatric precision medicine program in recurrent tumors: Results of the first 500 patients included in the European MAPPYACTS molecular profiling trial (2019) (3)
- Activation of the PI3K/Akt pathway in neuroblastoma (2007) (3)
- Predictive role of CD36 expression in HER2-positive breast cancer patients receiving neoadjuvant trastuzumab. (2022) (3)
- Understanding the biology and prognosis of PIK3CA gene mutations in primary breast cancer using gene expression profiling: A pooled analysis (2013) (3)
- Prospective Multicenter Study Validate a Prediction Model for Surgery Uptake Among Women with Atypical Breast Lesions (2020) (3)
- Corrigendum to "Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial" [Eur J Cancer 87 (2017) 122-130]. (2018) (3)
- EPAC-lung: European pooled analysis of the prognostic value of circulating tumour cells in small cell lung cancer (2021) (3)
- Characterization of Depressive Symptoms Trajectories After Breast Cancer Diagnosis in Women in France (2022) (3)
- Abstract PD6-5: Pooled analysis of circulating tumor cells in metastatic breast cancer: Findings from 1944 individual patients data (2013) (3)
- 161O Randomized preoperative window of opportunity (WOO) study with the CDK4/6 inhibitor abemaciclib in early breast cancer (EBC) patients and differential gene expression pathway analyses with palbociclib (2020) (3)
- P1-02-05: Invasive Lobular Carcinoma – A Luminal Breast Cancer Histotype Enriched for Epithelial-to-Mesenchymal Transition Features. (2011) (3)
- Abstract S4-4: Independent validation of Genomic Grade in the BIG 1-98 study (2012) (3)
- Single cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib resistant patients. (2022) (3)
- In regards to chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients (int j radiat oncol biol phys 2006;64:47-56). Baujat et al by. Authors' reply (2006) (3)
- EVALUATION OF PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL WHEN EVALUATING THE EFFECT OF CHEMOTHERAPY AND RADIOTHERAPY IN LOCALLY ADVANCED LUNG CANCER USING DATA FROM FOUR INDIVIDUAL PATIENT DATA META-ANALYSES (2011) (3)
- Individual patient data meta-analysis of neoadjuvant chemotherapy followed by surgery versus upfront surgery for carcinoma of the oesophagus or the gastro-oesophageal junction. (2021) (3)
- Dataset for: Multivariate joint frailty model for the analysis of nonlinear tumor kinetics and dynamic predictions of death (2018) (3)
- In reply to Drs. Huncharek and Kupelnick (2006) (3)
- Statistical methods applied to omics data: predicting response to neoadjuvant therapy in breast cancer (2014) (3)
- Five-gene signature in non-small-cell lung cancer. (2007) (3)
- Abstract OT2-10-02: Mypebs: An international randomized study comparing personalized, risk-stratified to standard breast cancer screening in women aged 40-70 (2022) (3)
- 14O_PR Biology of Breast Cancer Diagnosed in Young Women: Pooled Gene Expression Analysis From 3522 Patients (2012) (3)
- Validation of a new fully automated software for 2D digital mammographic breast density evaluation in predicting breast cancer risk (2021) (2)
- Abstract OT-38-01: MEDEA: A randomized trial of weight loss to reduce cancer-related fatigue (CRF) among overweight and obese breast cancer (BC) patients (2021) (2)
- 467 Radiomics to identify HER2 amplification or mutation in metastatic patients with solid tumors prospectively enrolled in MOSCATO-01 (2015) (2)
- [Gene expression profiling in cancer research]. (2007) (2)
- On the Use of Neural Networks with Censored Time-to-Event Data (2020) (2)
- Cxcr4 expression and risk of bone metastasis in patients with early breast cancer (2007) (2)
- Feasibility of developing reliable gene expression modules from FFPE derived RNA profiled on Affymetrix arrays (2018) (2)
- Dynamics of Long-Term Patient-Reported Quality of Life and Health Behaviors After Adjuvant Breast Cancer Chemotherapy (2022) (2)
- Multiple synchronous mechanisms may contribute to osimertinib resistance in non-small cell lung cancer (NSCLC) patients: Insights of the MATCH-R study (2019) (2)
- Group sequential adaptive designs in series of time-to-event randomised trials in rare diseases: A simulation study (2020) (2)
- Incidence and mortality rates of breast and gynecologic cancers and human development index in the pan-American region. (2014) (2)
- Overestimated treatment effects in randomised phase II trials: What's up doctor? (2019) (2)
- Molecular characterization of early-stage her2-overexpressing breast cancer (her2+ bc) treated with adjuvant trastuzumab: identification of prognostic groups (2012) (2)
- Erratum to: Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis (2016) (2)
- Breast cancer (BC) related fatigue: A longitudinal investigation of its prevalence, domains and correlates. (2018) (2)
- Clinical Usefulness of Microarrays for Cancer Prognosis in 2010—Letter (2010) (2)
- Adjuvant (cisplatin, etoposide, and 5-fluorouracil) chemotherapy after curative resection of gastric adenocarcinomas involving the esophagogastric junction. (1999) (2)
- Near-Infrared Fluorescence Axillary Reverse Mapping (ARM) Procedure in Invasive Breast Cancer: Relationship between Fluorescence Signal in ARM Lymph Nodes and Clinical Outcomes (2022) (2)
- Progression-free survival (PFS) as surrogate endpoint for overall survival (OS) in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer (MBC): An individual patient data (IPD) analysis. (2013) (2)
- A Phase II Study of Dovitinib in Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors After Failure of Two or More Tyrosine Kinase Inhibitors (2012) (2)
- Time to move forward from “first-generation” prognostic gene signatures in early breast cancer (2011) (2)
- Correction: Association between SPARC mRNA Expression, Prognosis and Response to Neoadjuvant Chemotherapy in Early Breast Cancer: A Pooled in-silico Analysis (2013) (2)
- Gene modules and pathological complete response to neoadjuvant chemotherapy in breast cancer. A pooled analysis. (2012) (2)
- EPAC-Lung: Pooled analysis of circulating tumor cells in advanced non-small cell lung cancer. (2019) (1)
- Correction: PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer (2019) (1)
- Meta‐analysis of clinical trials with competing time‐to‐event endpoints (2019) (1)
- Abstract P4-09-05: Microarray anlyses of breast cancers identify CH25H, a cholesterol gene, as a potential marker and target for late metastatic reccurences. (2012) (1)
- Complex Disease Individual Molecular Characterization Using Infinite Sparse Graphical Independent Component Analysis (2022) (1)
- Genome-wide expression profiling and tissue array analysis for prediction of recurrences in stage II-III colorectal cancer (CRC). (2006) (1)
- Progression-free survival (PFS) as a surrogate endpoint for overall survival (OS) in advanced/recurrent gastric cancer (AGC) treatment: Individual-patient-data (IPD) based meta-analysis of randomized trials. (2020) (1)
- Fatigue and health behaviors in cancer survivors: A cross-sectional population based study. (2017) (1)
- Correction: ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors (2019) (1)
- Genomic grade: Feasibility in routine practice and influence on treatment decision in early breast cancer. (2011) (1)
- Abstract P3-10-03: Receipt of breast cancer risk assessment and personalized prevention information among women diagnosed with a benign breast lesion (BBL) in a one stop breast unit: A prospective assessment (2016) (1)
- Predictive value of MRP2, p53, bcl2 and topoisomerase II immunostainings for the efficacy of anthracyclines-based adjuvant chemotherapy in breast cancer: Results from two randomized trials (2008) (1)
- Sustained cancer clinical trial activity in a French hospital during the first wave of the COVID-19 pandemic (2021) (1)
- Individual-specific networks for prediction modelling – A scoping review of methods (2022) (1)
- Abstract P6-07-14: Mutational and transcriptomic characterization of breast cancer (BC) arising in young patients (pts) and during pregnancy and their associations with long-term outcome (2012) (1)
- Association of Adherence to Endocrine Therapy Among Patients With Breast Cancer and Potential Drug-Drug Interactions (2022) (1)
- Use of genomic grade index to improve tumor grading of invasive lobular breast carcinoma. (2011) (1)
- A frequentist one-step model for a simple network meta-analysis of time-to-event data in presence of an effect modifier (2021) (1)
- Abstract 388: A benchmark study for identifying cancer drivers in the non-coding part of the genome (2017) (1)
- Study of BRAF mutations in melanoma and nevi from patients with germline mutation in the CDKN2A gene. (2006) (1)
- Axillary reverse mapping using near-infrared fluorescence imaging in invasive breast cancer (ARMONIC study). (2021) (1)
- Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic Cancer (2022) (1)
- An alternative trial-level measure for evaluating failure-time surrogate endpoints based on prediction error (2019) (1)
- Abstract LB-180: Epigenetic portraits of human breast cancers (2011) (1)
- Joint model imputation to estimate the treatment effect on long-term survival using auxiliary events (2017) (1)
- A two-stage drop-the-losers design for time-to-event outcome using a historical control arm (2021) (1)
- Informing the development of multidisciplinary interventions to help breast cancer patients return to work: a qualitative study (2022) (1)
- International study on inter-reader variability for circulating tumor cells in breast cancer (2014) (1)
- Surrogate endpoints for overall survival in loco-regionally advanced nasopharyngeal carcinoma: Results from the individual patient data meta-analysis MAC-NPC2 (2016) (1)
- Abstract 448: High prevalence of pathogenic germline variants in patients with oncogene-driven non-small cell lung cancer (2021) (1)
- Abstract PD3-7: Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analyses in breast cancer (2015) (1)
- Gene expression profiling of primary cutaneous melanoma: Expression of replication origins firing genes predicts clinical outcome. (2006) (1)
- Abstract 1867: Characterization of multiple driver alterations in acquired resistance to osimertinib inEGFR-mutated lung cancer: implementation of single cell approaches (2020) (1)
- Association between physical activity and neoadjuvant chemotherapy completion and pathologic complete response in primary breast cancer: the CANTO study (2022) (1)
- Comprehensive genome profiling in patients with metastatic non-small cell lung cancer: the precision medicine phase 2 randomized SAFIR02-Lung trial. (2022) (1)
- Abstract 318: Mechanisms of acquired resistance to FGFR inhibitors in molecularly-selected solid tumors: A prospective cohort from the MATCH-R study (2019) (1)
- Surrogate endpoints for overall survival (OS) in head and neck squamous cell carcinoma (HNSCC): Evaluation using individual data of 23,737 patients (2007) (1)
- Use of mutational profiling of metastatic ER+/HER2- breast cancers and the coexistence of KRAS, MET, BRAF, and FGFR3 with PIK3CA mutations. (2013) (1)
- Arsenic trioxide followed by autologous stem cell transplant for patients with relapsed APL. (2011) (1)
- Authors’ Reply to Schoenfeld: “Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors” (2017) (1)
- [The statistical challenge of false positives with microarrays]. (2008) (1)
- Abstract P6-07-22: Association between SPARC mRNA expression, prognosis and response to neoadjuvant chemotherapy in early breast cancer (BC): a pooledin-silicoanalysis (2012) (1)
- A microsimulation model to assess the economic impact of immunotherapy in non-small cell lung cancer (2020) (1)
- A gene signature of chemo-immunization to predict outcome in patients with triple negative breast cancer treated with neoadjuvant chemotherapy. (2017) (1)
- Outcome in colorectal cancer-tumour, stroma and so much more. (2018) (1)
- The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group (2021) (1)
- Effect of sample preservation method and transportation duration on tumor gene expression profiling in breast cancer. (2012) (1)
- PS945 KTE-X19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN ADULT PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA: END OF PHASE 1 RESULTS OF ZUMA-3 (2019) (1)
- In reply to: "Meyer CP et al., The association of hypoalbuminemia with early perioperative outcomes - A comprehensive assessment across 16 major procedures". (2017) (1)
- 72PPrognostic significance of tumor-infiltrating lymphocytes (TILs) in patients with early-stage triple-negative breast cancer (TNBC) treated with curative resection alone (2017) (1)
- Enhanced clinical assessment of hematologic malignancies through routine paired tumor:normal sequencing (2022) (1)
- 726PPrecision medicine for patients with advanced biliary tract cancers: Updated results from the prospective MOSCATO trial (2017) (0)
- Abstract P6-05-12: Comprehensive molecular analysis of estrogen receptor positive breast cancer to determine clinically actionable alterations (2013) (0)
- Reporting of endpoints and tracking of failures in randomized trials of radiotherapy or concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer (LA-HNSCC). (2009) (0)
- Use of oral complementary-alternative medicine (OCAM) and fatigue among early breast cancer (BC) patients (pts) (2020) (0)
- P41 Epidermal growth-factor receptor mutations and metastatic presentation in non-small-cell lung cancer (2011) (0)
- Abstract P1-15-03: Association between exercise, pathological complete response, and treatment tolerability in patients receiving neoadjuvant chemotherapy for operable breast cancer: Results from the CANTO study (2019) (0)
- Edinburgh Research Explorer PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer (2018) (0)
- A combination of resistance mechanisms is frequent in non-small cell lung cancer (NSCLC) that progressed to EGFR tyrosine kinase inhibitors (TKIs) (2019) (0)
- Abstract P4-11-01: Development of a clinico-bio-behavioral model for cancer-related fatigue (CRF) incorporating inflammatory biomarkers and proteomic data (2022) (0)
- Estimating the difference in restricted mean survival time accounting for trial effect in individual patient data meta-analyses (2020) (0)
- 135P Real-time genotyping-based breast cancer risk assessment in MyPeBS, an international randomized trial in the general population comparing risk-stratified to standard breast cancer screening (BCS) (2022) (0)
- Abstract P4-07-17: Association between plasma-based sequential windowed acquisition mass spectrometry (SWATH-MS) and invasive disease free survival (iDFS) in HR+/HER2- early breast cancer in the CANTO cohort (2022) (0)
- Abstract 4835: Gonosome-linked expression of PPP2R3B in cutaneous melanoma correlates with distant metastasis free survival (2011) (0)
- Gene-expression changes over time in a tamoxifen-treated breast cancer xenograft model. (2011) (0)
- Gene Modules and Response to Neoadjuvant Chemotherapy in Breast Cancer: A Meta-Analysis (2011) (0)
- Hyper-AdaC: Adaptive clustering-based hypergraph representation of whole slide images for survival analysis (2022) (0)
- Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized SAFIR02-LUNG trial and association with intracranial outcome. (2022) (0)
- Predictive ability of tumor growth modeling for overall survival in metastatic colorectal cancer. (2015) (0)
- Abstract P4-11-34: An integrated clinical, behavioral and biological model to predict the risk of weight gain among breast cancer survivors (BCS) (2022) (0)
- Abstract P3-05-14: Expression of the tumor associated carbohydrate antigen Tn and immune effectors in invasive breast cancer (2018) (0)
- Cost-Effectiveness Analysis of Sequential Treatment Strategies for Advanced Melanoma in Real Life in France (2022) (0)
- S15 Interpretation of microarray data in cancer: a statistical viewpoint (2007) (0)
- Feasibility study of cationic liposome-encapsulated paclitaxel in combination with paclitaxel followed by FEC as induction therapy in HER2-negative breast cancer (2013) (0)
- Abstract P3-05-03: Characterization of PIK3CA mutations in lobular breast cancer (2012) (0)
- Reply to V.P. Retèl et al, D. Gauchan et al, and C. Rahilly-Tierney et al. (2015) (0)
- [Individual patient data meta-analyses of randomized trials for the treatment of non-metastatic head and neck squamous cell carcinomas: Principles, results and perspectives]. (2015) (0)
- Baseline exhaled nitric oxide in relation to asthma control improvement after increasing inhaled steroids: A real life study (2013) (0)
- CustOmics: A versatile deep-learning based strategy for multi-omics integration (2022) (0)
- Changes in microRNAs spectrum during melanoma progression (2006) (0)
- External Quality Assessment 2.0: The Importance of a Standardized Implementation of TILs for Daily and Trial Practices (2022) (0)
- Impact of overweight, obesity, and post-treatment weight changes on occupational reintegration of breast cancer (BC) survivors. (2019) (0)
- Intraoperative parathyroid hormone testing in the monitoring of parathyroid surgery (2002) (0)
- Favoring the hierarchical constraint in penalized survival models for randomized trials in precision medicine (2023) (0)
- [Surgery or not on an atypical breast lesion? Taking anxiety into account in shared decision support from a prospective cohort of 300 patients]. (2021) (0)
- Prediction of treatment (tx)-induced fatigue in breast cancer (BC) patients (pts) using machine learning on genome-wide association (GWAS) data in the prospective CANTO cohort. (2019) (0)
- 167MO Longitudinal evaluation of serum assessed non-adherence to tamoxifen (TAM) among premenopausal patients (pts) in the prospective multicenter CANTO cohort (2020) (0)
- A time series evaluation of the in vivo effect of letrozole on gene expression in breast cancer. (2011) (0)
- Abstract PD5-06: The immunomodulatory potential of denosumab in breast cancer: results from D-BEYOND, a window of opportunity trial evaluating a RANK-ligand (RANKL) inhibitor and its biological effects in young pre-menopausal women diagnosed with early breast cancer (2019) (0)
- Role of the total mutation burden (TMB) and tumor-infiltrating lymphocytes (TILs) on the development of second primary cancer after complete resection of non-small cell lung cancer (NSCLC). (2020) (0)
- Molecular analysis for refractory rare cancers: sequencing battle continues: learnings for the MOSCATO-01 study. (2022) (0)
- Abstract 5224: Genome-wide interaction study of smoking and bladder cancer risk: results from the COBLAnCE cohort (2023) (0)
- Individual patient data meta-analysis of neoadjuvant chemotherapy followed by surgery versus upfront surgery in esophageal or gastro-esophageal carcinoma. (2021) (0)
- OC-0153 Immune infiltrate modulation induced by preoperative radiotherapy in breast cancer patients (2019) (0)
- A non-parametric Bayesian joint model for latent individual molecular profiles and survival in oncology (2022) (0)
- SO-5 Disease-free survival as surrogate for overall survival in neoadjuvant chemo(radio)therapy treatment of esophageal or gastro-esophageal junction carcinoma: An analysis of 4518 individual patients and 22 trials (2022) (0)
- Abstract 3418: Alterations in PIK3CA/PTEN as resistance mechanisms in lung cancer patients progressing on first-line next generation EGFR/ALK tyrosine kinase inhibitors (2023) (0)
- Phase II study of MLN8237 (Alisertib) in advanced/ metastatic sarcoma † (2016) (0)
- Abstract P2-08-08: Circulating tumor cells count-based nomograms to predict survival of metastatic breast cancer patients: Results from the European pooled analysis (2016) (0)
- Nonmetastatic inflammatory breast cancer: Evolution of invasive disease-free (IDFS) and overall survival (OS) over a 21-year period. (2014) (0)
- Development and Validation of Risk Prediction Models (2019) (0)
- Abstract PD9-05: Stromal tumor-infiltrating lymphocytes identify early-stage triple-negative breast cancer patients with favorable outcomes at 10-year follow-up in the absence of systemic therapy: a pooled analysis of 1835 patients (2023) (0)
- Abstract 3458: Resistance to selective FGFR inhibitors in FGFR-driven urothelial cancer (2023) (0)
- 487P Real-world feasibility of adjuvant TAC with pegylated G-CSF in resectable breast cancer: A single-center experience (2016) (0)
- Association of critical losses in X chromosome with melanoma progression: An EORTC Melanoma group study. (2008) (0)
- Overweight, obesity and weight gain after breast cancer (BC): A prospective clinical study. (2018) (0)
- Clinical implication of PIK3CA activating mutation in ER + HER2+ breast cancer: Based upon explorative mutational analysis of Neo-ALL-IN study (2016) (0)
- Abstract P3-04-10: Comparison between RNA-Seq and Affymetrix gene expression data (2012) (0)
- Abstract P3-12-12: ATTITUDE: Understanding and reducing ATTrition in longiTUDinal studiEs of cancer survivors (2022) (0)
- Physical activity (PA) and patterns of quality of life (QOL) after adjuvant chemotherapy (CT) for breast cancer (BC). (2018) (0)
- Views – Research Highlights News & Views A time series evaluation of the in vivo effect of letrozole on gene expression in breast cancer (2010) (0)
- All simulation models of breast cancer are wrong but some are useful. (2018) (0)
- Neuropathy and health behaviors in cancer survivors treated with chemotherapy (CT). (2018) (0)
- Melanoma gene expression profiling: prognostic markers and insight in tumor progression (2008) (0)
- 109P Characteristics of clonal hematopoiesis-related mutations identified in liquid biopsies from patients with metastatic solid tumors (2022) (0)
- Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer (NSCLC) patients. (2020) (0)
- Association between prothrombin rate, alpha-fetoprotein changes and survival of patients with advanced hepatocellular carcinoma (HCC) (2008) (0)
- P356: SUBGROUP ANALYSES OF KTE-X19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL) IN ZUMA-3 (2022) (0)
- Assessment of quality of life in patients with metastatic melanoma in real clinical practice in France. (2018) (0)
- Proteomic changes associated with breast cancer progression in the MCF10AT model. (2011) (0)
- CHANGES IN QUALITY OF LIFE AND SYMPTOM EXPERI- ENCE IN BREAST CANCER PATIENTS WITH ADJUVANT (2014) (0)
- Accounting for grouped predictor variables or pathways in high-dimensional penalized Cox regression models (2020) (0)
- Abstract P4-10-16: Reactive stroma and trastuzumab resistance in HER2-positive early breast cancer (2020) (0)
- Role of ALK activation in the development and maintenance of the neoplastic phenotype in neuroblastoma. (2009) (0)
- Differential impact of endocrine therapy (ET) and chemotherapy (CT) on quality of life (QoL) of 4,262 breast cancer (BC) survivors: A prospective patient-reported outcomes (PRO) analysis. (2019) (0)
- Abstract PD4-10: FGFR1 / ZNF217 copy numbers and outcome in patients with node positive, HR+/Her2- early breast cancer: A genomic analysis of PACS04 trial (2018) (0)
- An exonic expression profile for breast cancer diagnosis of fine needle aspiration biopsies. (2009) (0)
- 206POutcomes and predictive markers of trastuzumab-containing 1st-line chemotherapy in patients with HER2-positive advanced gastric cancer (2017) (0)
- Introduction to Clinical Trials (2019) (0)
- Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer (2022) (0)
- Prediction of treatment benefit in high-dimensional cox models via gene signatures in randomized clinical trials (2015) (0)
- The Glasgow Microenvironment Score and risk and site of recurrence in TNM I–III colorectal cancer (2022) (0)
- Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancer (2022) (0)
- P4-07-14: Circulating Tumor Cells (CTCs) Detection and HER2 Profiling by CellSearch® in Non-Metastatic Breast Cancer: An International Ring Study To Assess Inter-Reader Variability. (2011) (0)
- Impact of changes in airway calibre on FENO ability to reflect asthma control (2014) (0)
- Molecular profile characterization and impact on clinical outcome in metastatic NSCLC patients enrolled in MOSCATO 01 trial. (2017) (0)
- Abstract 358: A prospective study of prostate cancer metastases identifies an androgen receptor activity-low, stemness program associated with resistance to androgen receptor axis inhibitors and unveils mechanisms of clonal evolution (2021) (0)
- 225P Impact of potential drug-drug interactions (PDDI) on adherence to endocrine therapy (ET) among patients with breast cancer (BC) in the Health Improvement Network (THIN) (2022) (0)
- Precision medicine for patients with rare cancers: An effective strategy within the prospective MOSCATO trial. (2018) (0)
- [Network meta-analyses: Interest and limits in oncology]. (2016) (0)
- Predictive value of p27 for the benefit of adjuvant anthracycline-based chemotherapy in early breast cancer. (2009) (0)
- Characterization of PI3KCA Mutation in Lobular Breast Cancer. (2012) (0)
- A two‐stage drop‐the‐losers design for time‐to‐event outcome using a historical control arm (2021) (0)
- Abstract PD5-02: Not presented (2018) (0)
- Interaction between airway calibre and exhaled nitric oxide: the allergen challenge model (2013) (0)
- 1168PEstimation of benefice to anti-PD-(L)1 for metastatic patients by real-time quantitative and functional estimation of immune infiltrate with RNAseq (2017) (0)
- Prognostic implications of residual disease (RD) tumor-infiltrating lymphocytes (TIL) in triple negative breast cancer (TNBC) after neo-adjuvant chemotherapy (NAC). (2018) (0)
- High resolution oligonucleotide array-CGH to identify therapeutic targets in breast cancer (2008) (0)
- SO-4 Individual participant data network meta-analysis (IPD-NMA) of neoadjuvant chemotherapy or chemoradiotherapy in esophageal or gastro-esophageal junction carcinoma (2022) (0)
- Running title : CTCs and staging in MBC (2018) (0)
- QL4 - ASSESSMENT OF QUALITY OF LIFE IN PATIENTS WITH METASTATIC MELANOMA IN REAL CLINICAL PRACTICE IN FRANCE (2018) (0)
- PD03-10: Gene Modules and Response to Neoadjuvant Chemotherapy in Breast Cancer: A Meta-Analysis. (2011) (0)
- Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer (2022) (0)
- Interaction between airway calibre and exhaled nitric oxide: impact on asthma control assessment (2013) (0)
- Urokinase-type plasminogen activator gene (PLAU) to predict clinical outcome in invasive lobular carcinoma. (2012) (0)
- Evaluating Personalized Medicine in Multi-marker Multi-treatment Clinical Trials: Accounting for Heterogeneity (2017) (0)
- Evaluating methods for Lasso selective inference in biomedical research: a comparative simulation study (2020) (0)
- Abstract 2953: Overall survival results of the single-institution molecular screening MOSCATO trial in hard-to-treat advanced cancers (2018) (0)
- Restricted mean survival and hazard ratios (2016) (0)
- A new genomic approach to describe the natural history of node negative breast cancer patients. (2006) (0)
- Abstract 5528: The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene (2017) (0)
- IBS31.01 Endpoints and Trial Design for Oncogene Addicted NSCLC (2019) (0)
- PCN96 COST-EFFECTIVENESS OF TREATMENT SEQUENCES FOR BRAF WILD-TYPE METASTATIC MELANOMA IN REAL LIFE IN FRANCE (2019) (0)
- Weight loss, physical and psychological patient reported outcomes (PROs) among obese patients (pts) with early breast cancer (BC). (2018) (0)
- Abstract 2230: Integrative genomic analysis of refractory metastatic cancer (2021) (0)
- Genomic grade index improves tumor grading of invasive lobular breast carcinoma (2011) (0)
- Assessing the risk of severe post-treatment (tx) cancer-related fatigue (CRF) among breast cancer survivors (BCS) in the CANcer TOxicity (CANTO) cohort. (2021) (0)
- Assessing the Value of Surrogate Endpoints (2019) (0)
- 493 Prognostic factors to predict outcomes in patients with HER2-overexpressing metastatic breast cancer treated with trastuzumab containing chemotherapy as first or second line therapy: prognosis grouping according to the prognostic factors (2010) (0)
- Evaluation of PI3K-pathway–activation status in matched primary (P) and metastatic (M) ER+/HER2- breast cancer (BC) lesions according to PIK3CA-mutation status. (2014) (0)
- High-Dimensional, Penalized-Regression Models in Time-to-Event Clinical Trials (2019) (0)
- Abstract P4-11-09: Cancer-related cognitive impairment (CRCI) in early breast cancer (BC) survivors (2022) (0)
- Abstract 311: Diverse biological mechanisms drive resistance to Lorlatinib in ALK-rearranged Lung Cancer (2019) (0)
- Molecular screening in advanced cancer patients with head and neck cancers: A retrospective analysis of the MOSCATO-01 trial. (2018) (0)
- Predictors of responses to immune checkpoint blockade in advanced melanoma (2017) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Stefan Michiels?
Stefan Michiels is affiliated with the following schools:
